anti-b7-h4/anti-4-1bb bispecific antibody cln-418: sourced relationships with 1 company · 1 clinical trial tracked.
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could anti-b7-h4/anti-4-1bb bispecific antibody cln-418 → CGEM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
No additional listed-company sponsor is linked.
| Company | Dated record stage |
|---|---|
| Cullinan Therapeutics, Inc. (CGEM) Patients with advanced solid tumors; targets cancers with hi… | Phase 1/Phase 2 |
Cullinan reported ending its CLN-418 license effective November 2024, discontinuing development and returning development and commercial rights to Harbour. Harbour’s current development activity is unknown.
Cullinan CLN-418 license; termination effective November 2024 · 2025-02-27 · SEC source
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CLN-418 in Subjects With Advanced Solid Tumors
Primary endpoint: Proportion of subjects with dose-limiting toxicity (DLT)
anti-b7-h4/anti-4-1bb bispecific antibody cln-418 has dated SEC/FDA relationship records for Cullinan Therapeutics, Inc..
BioSniper tracks 1 clinical trial involving anti-b7-h4/anti-4-1bb bispecific antibody cln-418.